VBI Vaccines’s $71.9 Million underwritten public offering and concurrent registered direct offering of common shares


Haynes and Boone, LLP represented client VBI Vaccines Inc. in its successful underwritten public offering and concurrent registered direct offering of common shares for aggregate gross proceeds of approximately $71.9 million.

VBI Vaccines (Nasdaq: VBIV), based in Cambridge, Massachusetts, is a commercial-stage biopharmaceutical company developing next-generation infectious disease and immuno-oncology vaccines, such as vaccines to prevent hepatitis B (HBV), cytomegalovirus (CMV) and glioblastoma multiforme (GBM).

BMO Capital Markets and Canaccord Genuity acted as book-runners, and Ladenburg Thalmann acted as lead manager for the underwritten public offering.

Haynes and Boone, LLP represented client VBI Vaccines Inc. with Rick Werner (Picture), Jayun Koo and Pat Horan.

Involved fees earner: Rick Werner – Haynes and Boone; Jayun Koo – Haynes and Boone; Patrick Horan – Haynes and Boone;

Law Firms: Haynes and Boone;

Clients: VBI Vaccines Inc.;

Avatar

Author: Ambrogio Visconti